Developer docs
API playgroundTry for free, no card

Search company profiles

HM Venture Partners

Full company profile

uuid003wido

Namestring
HM Venture Partners
Legal namestring
HM Venture Partners
Company typeenum
Private
Founded yearint
2019
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
healthcare venture capital, biotech investment, medtech investment, early-stage financing, growth-stage equity
Industry1 code
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
NAICS code1 code
  • Portfolio Management and Investment Advice523940
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital (Healthcare)
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Fund Management Fees
TypeSubscription Recurring
Description

Collects management fees from its three funds under management as a standard VC practice

hmventurepartners.com
2Carried Interest/Performance Fees
TypeTransaction Fee
Description

Earned through successful exits and returns from portfolio companies such as OncoImmune (acquired by Merck), KBP (acquired by Novo Nordisk), Urotronic (acquired by Laborie), Arthrosi (acquired by Sobi), and Sagimet (IPO)

hmventurepartners.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Others
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1HM Healthcare Fund I
Description

Third fund launched to primarily invest in healthcare breakthroughs in the US

hmventurepartners.com
+2 more records
Core offering1 text field

HM Venture Partners is a healthcare venture capital firm that invests equity capital from its three funds (HM Healthcare Fund I, II, and III) into early and growth-stage biotech and medtech companies globally. Beyond capital, the firm provides operational support, strategic advisory, FDA approval guidance, clinical trial site access, and introductions to distribution channels including the Chinese market, leveraging its Mayo Clinic and Hillhouse ecosystem.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • OncoImmune acquired by Merck for $425M upfront plus milestones and spin-off shares
+3 more records
Product overview1 text field

HM Venture Partners operates as a healthcare venture capital firm managing three investment funds (HM Healthcare Fund I, II, and III) with combined AUM exceeding $600M. The firm provides investment services to early and growth-stage biotech and medtech companies globally. Their investment offering includes capital deployment, operational support, and leveraging their ecosystem of academic institutions, physician networks, and industry experts to support portfolio companies.

Product and service3 records
1HM Healthcare Fund I
CategoryInvestment Fund
Description

Healthcare-focused venture capital fund under HM Venture Partners management, primarily investing in healthcare breakthroughs in the US market.

2HM Healthcare Fund II
CategoryInvestment Fund
Description

Second healthcare-focused investment fund under HM Venture Partners management.

3HM Healthcare Fund III
CategoryInvestment Fund
Description

Third healthcare-focused investment fund under HM Venture Partners management; one of three funds contributing to combined AUM in excess of $600M.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2014-01-01
Description

Co-founded HM Healthcare Management Services (HMHMS) with Hillhouse Investment Group and Mayo Clinic in 2014. This partnership established HM Venture Partners' foundational relationship with Mayo Clinic, enabling access to clinical networks, deal flow, and co-investment opportunities. Mayo Clinic physicians and business leaders are investors in HM's funds.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-founded HM Healthcare Management Services (HMHMS) with Hillhouse Investment Group and Mayo Clinic in 2014. Hillhouse provides capital and resources that support HM's investment activities.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

OrbiMed is the world's largest healthcare-dedicated investment firm, investing across all stages from venture through public markets. Comparable as a sector-focused healthcare VC incumbent competing for the same biotech/medtech deals and LP capital.

TypeDirect peer
Description

Atlas Venture is an early-stage biotech-focused venture firm that builds companies from inception. Comparable as a healthcare-specialist VC of similar scale focused on company formation and Series A biotech investing.

TypeBroad incumbent
Description

RA Capital is a multi-stage healthcare investment manager combining public and private healthcare investing. Comparable as a large healthcare-focused peer with both fund-of-funds and direct investment capabilities serving similar LPs.

TypeDirect peer
Description

Vivo Capital is a US healthcare-focused venture and growth firm with strong cross-border US–Asia capability. Directly comparable to HMVP given its similar sector specialization, multi-fund structure, and emphasis on healthcare investments spanning biotech, medtech, and cross-border opportunities.

TypeBroad incumbent
Description

ARCH is one of the largest and most established US biotech/medtech venture firms, investing across stages with deep ties to academic institutions. Comparable as a healthcare-specialist incumbent with academic-ecosystem deal sourcing akin to HMVP's Mayo Clinic relationship.

TypeDirect peer
Description

Third Rock Ventures is a healthcare-focused VC that builds biotech companies from inception with deep ties to academic medical centers. Comparable as a healthcare-specialist firm with academic-medical-center sourcing analogous to HMVP's Mayo Clinic ecosystem.

TypeDirect peer
Description

5AM Ventures is a healthcare-focused early-stage venture firm investing in biotech and medtech. Comparable as a similarly sized healthcare specialist competing in Series A–B rounds across the same therapeutic areas as HMVP.

TypeDirect peer
Description

Versant is a healthcare-focused VC firm investing in biotech, medtech, and healthcare services across stages. Comparable given its dedicated healthcare focus, multiple funds, and emphasis on building companies from inception, similar to HMVP's Mayo-rooted strategy.

TypeDirect peer
Description

Sofinnova is a healthcare-specialist VC with decades of experience in biotech and medtech investing across stages. Comparable as a similarly sized sector-focused peer with cross-stage healthcare strategies targeting similar therapeutic and device themes.

TypeRegional player
Description

Forbion is a leading European healthcare-dedicated VC firm investing in biotech and medtech. Comparable as a healthcare-specialist VC with multi-fund AUM and similar stage focus, though primarily serves the European ecosystem.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment3 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

HM Venture Partners

Venture Capital (Healthcare)hmventurepartners.com

HM Venture Partners firmographics

Firmographics
Name
HM Venture Partners
Legal name
HM Venture Partners
Website
https://hmventurepartners.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

HM Venture Partners industry classification

Industry
Product category
Venture Capital (Healthcare)
NAICS
Portfolio Management and Investment Advice (523940)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)

Keywords

  • Healthcare venture capital
  • Biotech investment
  • Medtech investment
  • Early-stage financing
  • Growth-stage equity

Where HM Venture Partners is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices4 records

Markets served

HM Venture Partners business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

  1. Fund Management Fees: Collects management fees from its three funds under management as a standard VC practice
  2. Carried Interest/Performance Fees: Earned through successful exits and returns from portfolio companies such as OncoImmune (acquired by Merck), KBP (acquired by Novo Nordisk), Urotronic (acquired by Laborie), Arthrosi (acquired by Sobi), and Sagimet (IPO)

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

HM Venture Partners product offering

Product offering

Core offering

HM Venture Partners is a healthcare venture capital firm that invests equity capital from its three funds (HM Healthcare Fund I, II, and III) into early and growth-stage biotech and medtech companies globally. Beyond capital, the firm provides operational support, strategic advisory, FDA approval guidance, clinical trial site access, and introductions to distribution channels including the Chinese market, leveraging its Mayo Clinic and Hillhouse ecosystem.

Product overview

HM Venture Partners operates as a healthcare venture capital firm managing three investment funds (HM Healthcare Fund I, II, and III) with combined AUM exceeding $600M. The firm provides investment services to early and growth-stage biotech and medtech companies globally. Their investment offering includes capital deployment, operational support, and leveraging their ecosystem of academic institutions, physician networks, and industry experts to support portfolio companies.

Differentiator

Problem solved

Functional benefit

Brands

  • HM Healthcare Fund I: Third fund launched to primarily invest in healthcare breakthroughs in the US
  • HM Healthcare Fund II
  • HM Healthcare Fund III

Products and services

  • HM Healthcare Fund I Healthcare-focused venture capital fund under HM Venture Partners management, primarily investing in healthcare breakthroughs in the US market.
  • HM Healthcare Fund II Second healthcare-focused investment fund under HM Venture Partners management.
  • HM Healthcare Fund III Third healthcare-focused investment fund under HM Venture Partners management; one of three funds contributing to combined AUM in excess of $600M.

Quantifiable outcome

  • OncoImmune acquired by Merck for $425M upfront plus milestones and spin-off shares
  • +3 more outcomes

Companies that use HM Venture Partners

Customer profile

Segments2 records

Ideal customer profiles2 records

HM Venture Partners technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

HM Venture Partners partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Mayo CliniccoreStrategic or Co-development Partner · 1 January 2014Co-founded HM Healthcare Management Services (HMHMS) with Hillhouse Investment Group and Mayo Clinic in 2014. This partnership established HM Venture Partners' foundational relationship with Mayo Clinic, enabling access to clinical networks, deal flow, and co-investment opportunities. Mayo Clinic physicians and business leaders are investors in HM's funds.
  • Hillhouse Investment GroupcoreStrategic or Co-development PartnerCo-founded HM Healthcare Management Services (HMHMS) with Hillhouse Investment Group and Mayo Clinic in 2014. Hillhouse provides capital and resources that support HM's investment activities.

Scale indicators5 records

Recent moves8 records

Expansion highlights5 records

HM Venture Partners competitors and assessment

Company assessment

Broad incumbents

  • OrbiMed: OrbiMed is the world's largest healthcare-dedicated investment firm, investing across all stages from venture through public markets. Comparable as a sector-focused healthcare VC incumbent competing for the same biotech/medtech deals and LP capital.
  • RA Capital Management: RA Capital is a multi-stage healthcare investment manager combining public and private healthcare investing. Comparable as a large healthcare-focused peer with both fund-of-funds and direct investment capabilities serving similar LPs.
  • ARCH Venture Partners: ARCH is one of the largest and most established US biotech/medtech venture firms, investing across stages with deep ties to academic institutions. Comparable as a healthcare-specialist incumbent with academic-ecosystem deal sourcing akin to HMVP's Mayo Clinic relationship.

Direct peers

  • Atlas Venture: Atlas Venture is an early-stage biotech-focused venture firm that builds companies from inception. Comparable as a healthcare-specialist VC of similar scale focused on company formation and Series A biotech investing.
  • Vivo Capital: Vivo Capital is a US healthcare-focused venture and growth firm with strong cross-border US–Asia capability. Directly comparable to HMVP given its similar sector specialization, multi-fund structure, and emphasis on healthcare investments spanning biotech, medtech, and cross-border opportunities.
  • Third Rock Ventures: Third Rock Ventures is a healthcare-focused VC that builds biotech companies from inception with deep ties to academic medical centers. Comparable as a healthcare-specialist firm with academic-medical-center sourcing analogous to HMVP's Mayo Clinic ecosystem.
  • 5AM Ventures: 5AM Ventures is a healthcare-focused early-stage venture firm investing in biotech and medtech. Comparable as a similarly sized healthcare specialist competing in Series A–B rounds across the same therapeutic areas as HMVP.
  • Versant Ventures: Versant is a healthcare-focused VC firm investing in biotech, medtech, and healthcare services across stages. Comparable given its dedicated healthcare focus, multiple funds, and emphasis on building companies from inception, similar to HMVP's Mayo-rooted strategy.
  • Sofinnova Investments: Sofinnova is a healthcare-specialist VC with decades of experience in biotech and medtech investing across stages. Comparable as a similarly sized sector-focused peer with cross-stage healthcare strategies targeting similar therapeutic and device themes.

Regional players

  • Forbion: Forbion is a leading European healthcare-dedicated VC firm investing in biotech and medtech. Comparable as a healthcare-specialist VC with multi-fund AUM and similar stage focus, though primarily serves the European ecosystem.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

HM Venture Partners financial estimates

Financial estimate

Revenue estimate

Valuation estimate

HM Venture Partners leadership team

Management profile

Number of profiles

Profiles7 records

HM Venture Partners funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

HM Venture Partners M&A and investment

M&A and investment

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HM Venture Partners

What does HM Venture Partners do?

HM Venture Partners is a healthcare venture capital firm that invests equity capital from its three funds (HM Healthcare Fund I, II, and III) into early and growth-stage biotech and medtech companies globally. Beyond capital, the firm provides operational support, strategic advisory, FDA approval guidance, clinical trial site access, and introductions to distribution channels including the Chinese market, leveraging its Mayo Clinic and Hillhouse ecosystem.

Is HM Venture Partners a public or private company?

HM Venture Partners is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was HM Venture Partners founded?

HM Venture Partners was founded in 2019. It employs 1 to 10 people.

Where is HM Venture Partners based?

HM Venture Partners is headquartered in San Francisco, United States, in the North America region.

How does HM Venture Partners make money?

Two revenue lines are on record. Fund Management Fees are the primary driver. The others are carried Interest/Performance Fees.

Who are HM Venture Partners's main competitors?

Broad incumbents on record are OrbiMed, RA Capital Management and ARCH Venture Partners. Direct peers are Atlas Venture, Vivo Capital, Third Rock Ventures, 5AM Ventures, Versant Ventures and Sofinnova Investments. Forbion is listed as a regional player.

Does HM Venture Partners have an API?

No public API is recorded for HM Venture Partners.

What industry is HM Venture Partners in?

HM Venture Partners's product category is Venture Capital (Healthcare). Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Minnesota Medical Technologies: $20.6 Million Raised To Commercialize StaySureMinnesota Medical Technologies has raised $20.6 million in a Series A preferred equity financing round co-led by HM Venture Partners and Southeast Minnesota Capital Partners to accelerate the commercialization of its FDA-cleared fecal incontinence treatment device StaySure in the United States. The funding will support the company's nationwide rollout, including building operational and distribution infrastructure, expanding its team across sales and marketing, and reducing debt. The device, which received FDA 510(k) clearance in July 2025 following clinical testing at Mayo Clinic, addresses a condition affecting more than 2% of the global population in a market currently served primarily by absorbent products.BioSpaceArthrosi Secures $153 Million in Series E Financing to Complete Pivotal Development of Pozdeutinurad for the Treatment of Gout and Tophaceous GoutArthrosi Therapeutics has closed a $153 million Series E financing round led by Prime Eight Capital Limited, with participation from CR Biotech, HighLight Capital, HM Venture Partners, ReliantTech Limited, and existing shareholders. The company plans to use the proceeds to complete its pivotal Phase 3 REDUCE 1 and REDUCE 2 studies evaluating pozdeutinurad (AR882) for the treatment of gout and tophaceous gout, with both trials now fully enrolled. The company expects to report pivotal data in Q2 2026.PR NewswireArthrosi Secures $153 Million in Series E Financing to Complete Pivotal Development of Pozdeutinurad for the Treatment of Gout and Tophaceous GoutArthrosi Therapeutics closed a $153 million Series E financing round led by Prime Eight Capital Limited, with participation from CR Biotech, HighLight Capital, HM Venture Partners, ReliantTech Limited, and existing shareholders. The proceeds will fund completion of the pivotal Phase 3 REDUCE 1 and REDUCE 2 studies for pozdeutinurad (AR882), a next-generation URAT1 inhibitor for treating gout and tophaceous gout. Both Phase 3 trials are now fully enrolled, with pivotal data expected in Q2 2026.PR NewswireHarry Hoffman and David Herbert join the HM Venture Partners team as Venture PartnersHM Venture Partners, a San Francisco-based healthcare venture capital firm, announced that Harry Hoffman and David Herbert have joined as Venture Partners. Both individuals previously held senior roles at Mayo Clinic, including Chief Investment Officer and Chief Administrative Officer positions, and co-founded Southeast Minnesota Capital Partners in 2021. The hires are expected to enhance HMVP's proprietary deal sourcing capability and expand its global vision and execution capabilities.